Aktienanalyse wird geladen …
BAX · NYSE · Medical Devices · USA
23,48 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 11,24 Mrd. | -957 Mio. | -1,87 $ | 513 Mio. | 5 Mio · 1 % | 2 Mio · 0,4 % | 30,1 % | -8,5 % | 0,65 $ | 0,23 $ | 0,52 $ |
| 2024 | 10,64 Mrd. | -649 Mio. | -1,27 $ | 510 Mio. | 4,9 Mio · 1 % | — | 37,5 % | -6,1 % | 1,12 $ | 0,22 $ | 1,04 $ |
| 2023 | 10,36 Mrd. | 2,66 Mrd. | 5,23 $ | 508 Mio. | 4,9 Mio · 1 % | — | 40,1 % | 25,6 % | 2,55 $ | 0,23 $ | 1,16 $ |
| 2022 | 10,06 Mrd. | -2,43 Mrd. | -4,83 $ | 504 Mio. | 6 Mio · 1,2 % | — | 35,3 % | -24,2 % | 1,65 $ | 0,28 $ | 1,15 $ |
| 2021 | 12,15 Mrd. | 1,28 Mrd. | 2,53 $ | 508 Mio. | 6,2 Mio · 1,2 % | 15,2 Mio · 3 % | 38,9 % | 10,6 % | 3,01 $ | 0,29 $ | 1,09 $ |
| 2020 | 11,67 Mrd. | 1,1 Mrd. | 2,13 $ | 517 Mio. | 5,5 Mio · 1,1 % | 7,5 Mio · 1,5 % | 39,3 % | 9,4 % | 2,24 $ | 0,25 $ | 0,96 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,96 Mrd. | 126 Mio. | 0,24 $ | 518 Mio. | 34,9 % | 4,3 % |
| Q1 2026 | 2,7 Mrd. | -15 Mio. | -0,03 $ | 515 Mio. | 33 % | -0,6 % |
| Q4 2025 | 2,97 Mrd. | -1,13 Mrd. | -2,20 $ | 514 Mio. | 19,4 % | -37,9 % |
| Q3 2025 | 2,84 Mrd. | -46 Mio. | -0,09 $ | 514 Mio. | 33,5 % | -1,6 % |
| Q2 2025 | 2,81 Mrd. | 91 Mio. | 0,18 $ | 514 Mio. | 35,3 % | 3,2 % |
| Q1 2025 | 2,63 Mrd. | 126 Mio. | 0,25 $ | 514 Mio. | 32,8 % | 4,8 % |
| Q4 2024 | 2,75 Mrd. | -512 Mio. | -1,00 $ | — | 34,8 % | -18,6 % |
| Q3 2024 | 2,7 Mrd. | 140 Mio. | 0,27 $ | 512 Mio. | 38,3 % | 5,2 % |
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest BAX und jede andere Aktie unbegrenzt.